Irabel

Irbesartan, the active ingredient in Irabel, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is used to lower blood pressure and protect kidney function in patients with hypertension, diabetic nephropathy, or heart failure.

GNH USA supplies Irabel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Irabel (irbesartan) acts on the renin‑angiotensin‑aldosterone system to manage several cardiovascular and renal conditions. - Hypertension: Reduces systolic and diastolic blood pressure, decreasing risk of stroke and heart attack. - Diabetic nephropathy: Slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: Improves symptoms and reduces hospitalisation in patients with chronic heart failure. - Left ventricular hypertrophy: Contributes to regression of cardiac remodeling in hypertensive patients.

Irabel may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Cough - Hyperkalaemia - Increased serum creatinine

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute renal failure - Hepatic injury - Neutropenia - Anaphylactoid reaction

Before initiating Irabel, several safety considerations should be observed. - Blood pressure monitoring: Check regularly to avoid excessive hypotension. - Renal function assessment: Evaluate serum creatinine and eGFR before initiation and during therapy. - Electrolyte surveillance: Monitor potassium levels, especially in patients with renal impairment or on potassium‑sparing agents. - Pregnancy consideration: Use only if potential benefit justifies risk; avoid in second and third trimester. - Drug discontinuation: Do not stop abruptly in patients with heart failure; taper under medical supervision. - Store at ambient temperature: Keep below 25 °C, in original container, protected from moisture and light.

Irabel can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: May cause dangerous hyperkalaemia. - Aliskiren in diabetic patients: Increases risk of renal impairment and hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): Can raise irbesartan plasma levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: Additive blood pressure lowering, risk of hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): May reduce antihypertensive effect and impair renal function. - Lithium: May increase lithium levels, requiring monitoring.